Q4 2023 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2024-02-14 · accession 0001493152-24-006653
$376.1M
Reported value
46
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $42.8M | 11.4% | 3,820,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $37.8M | 10.1% | 2,215,000 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $30.9M | 8.22% | 4,146,138 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $28.0M | 7.46% | 610,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $27.1M | 7.20% | 6,070,000 | Common | SOLE |
| 14888U101 | CPRX | CATALYST PHARMACEUTICALS INC | $21.4M | 5.70% | 1,257,200 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $14.2M | 3.78% | 357,500 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $11.1M | 2.95% | 311,500 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $11.1M | 2.95% | 2,529,887 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS INC | $10.9M | 2.91% | 307,500 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $10.9M | 2.89% | 263,700 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $9.3M | 2.47% | 3,045,525 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $8.6M | 2.28% | 200,000 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $7.6M | 2.03% | 699,000 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $7.3M | 1.94% | 897,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $6.3M | 1.68% | 1,960,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS INC | $6.3M | 1.66% | 308,500 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $6.1M | 1.63% | 563,500 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $5.7M | 1.50% | 90,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $5.4M | 1.42% | 445,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $5.0M | 1.34% | 2,692,594 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $4.8M | 1.28% | 320,000 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $4.6M | 1.23% | 250,000 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS | $3.7M | 0.97% | 1,092,500 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $3.6M | 0.97% | 877,000 | Common | SOLE |
| 09075X108 | — | BRIDGEBIO PHARMA INC | $3.6M | 0.96% | 496,500 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $3.4M | 0.90% | 2,535,000 | Common | SOLE |
| 471871103 | — | JASPER THERAPEUTICS INC | $3.1M | 0.84% | 3,985,340 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $3.0M | 0.80% | 99,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $3.0M | 0.79% | 265,388 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $2.9M | 0.78% | 8,000,000 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $2.8M | 0.75% | 623,500 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $2.8M | 0.75% | 1,140,000 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $2.8M | 0.74% | 359,370 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $2.7M | 0.72% | 2,982,200 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.6M | 0.69% | 112,700 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $1.8M | 0.49% | 150,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $1.7M | 0.46% | 211,400 | Common | SOLE |
| B6S7WD106 | NYXH | NYXOAH S A | $1.6M | 0.43% | 344,800 | Common | SOLE |
| 617760202 | MOR2 | MORPHOSYS AG | $1.4M | 0.38% | 145,000 | Common | SOLE |
| 74017N105 | PGEN | PRECIGEN INC | $1.4M | 0.36% | 1,012,500 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $1.3M | 0.34% | 301,491 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.1M | 0.29% | 975,000 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $877,500 | 0.23% | 130,000 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $861,208 | 0.23% | 1,297,000 | Common | SOLE |
| G5269C101 | — | KINIKSA PHARMACEUTICALS LTD | $640,210 | 0.17% | 37,500 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.